Eurofins CDMO Alphora Expands Kilolab and High Potency Development and Manufacturing Capabilities

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Eurofins CDMO Alphora Expands Kilolab and High Potency Development and Manufacturing CapabilitiesAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.MISSISSAUGA, Ontario — Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities in Mississauga.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe expanded laboratories are designed to support the growing demand for enhanced flexibility as part of process development, scale-up, and manufacturing activities for non-high potent and high potent programs. Together, the suites cover 627 square feet. They are equipped with walk-in fume hoods capable of supporting up to 100L glass reactors and utilise a flexible design so that specialised equipment such as isolators, glove boxes, and lyophilizers can fulfill project requirements as needed, enabling efficient execution of a wide range of non-high potent and high potent programs.The laboratories are further supported by an additional dedicated analytical laboratory and an adjacent GMP warehouse, creating an integrated environment that streamlines development workflows, analytical support, material management, and manufacturing readiness.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againThis expansion strengthens Eurofins CDMO Alphora’s established expertise in small molecule development and manufacturing, complementing its comprehensive service offerings in process research and development, analytical development, GMP manufacturing, and commercialization support. This expansion allows Eurofins CDMO Alphora to better support increasingly complex and highly potent molecules across various stages of development while maintaining a strong focus on quality, safety, and operational excellence. The expanded capability also further supports the site’s fully integrated ADC offering, producing linkers and payloads for conjugation with mAbs manufactured on site, significantly reducing timelines and supply chain complexities.As demand continues to grow for targeted therapies and next-generation medicines, this expanded capacity reinforces Eurofins CDMO Alphora’s commitment to providing flexible, science-driven solutions that help partners accelerate the development of life-changing therapies.To learn more, please visit: https://www.eurofins.com/en/biopharma-services/cdmo/About Eurofins CDMO Alphora Eurofins CDMO Alphora, part of the global network of Eurofins laboratories, develops and manufactures small molecule and biologic drug substances and drug products “under one roof” in Mississauga, Ontario, Canada. Our small molecule capabilities include the development and manufacture of APIs and HPAPIs, oral drug products and API solid-state R&D. Our biologics capabilities include the development and manufacture of mAbs, proteins and ADCs, and Sterile Fill (2026). Established in 2003, our FDA, Health Canada, and Japan PMDA inspected site is home to 250 employees.View source version on businesswire.com: Senior Vice President, Business OperationsThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.